DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2026
INDEX
Etretinate (Cont.):
standard dosing range, 1811t
structure of, 1811t
Eubacterium lentum, and resistance to
digoxin, 803
EULEXIN (flutamide), 1668t–1670t,
1841
EURAX (crotamiton), 1819
EVAMIST (estradiol), 1839t
Everolimus, 1013, 1743
drug interactions with, 1744
therapeutic uses of, 1744
EVICEL (fibrinogen glue), 1790
EVISTA (raloxifene), 1756
Evolution, antimicrobial resistance
and, 1377–1378
Exchangers, 95
Excitable gap, 823f
Excitation-contraction coupling, in
gastrointestinal smooth
muscle, 1324
Excitatory neurotransmission, 183f
Excitatory postsynaptic potential
(EPSP), 184
Excretion of drugs, 26–27
ABC transporters in, 105t–106t
anticholinesterase agents, 247
biliary, 26
epinephrine, 286
fecal, 26
isopreoterenol, 289
norepinephrine, 287
saliva and, 26–27
unchanged urinary
of common drugs, 1809t–1890t
as pharmacodynamic parameter,
1802–1803
Exemestane, 1757t, 1760f, 1762–1763
Exenatide, 1263
pharmacokinetics of, 1840t
Exocrine glands
H 1
-receptor antagonists and, 919
nicotine and, 271
Exons, 148f
Expectorants, 1057
Expression regulation, of transporters,
97
Extended-release preparations, 21
Extent of availability, 1802
Extracellular fluid (ECF), volume,
diuretics and, 677f
Extracellular fluid volume (ECFV)
distribution of, and blood pressure
regulation, 698f
and edema formation, 696–698, 698f
Extracorporeal photopheresis (ECP),
1814–1815
Extramedullary toxicity, of alkylating
agents, 1682t
Extraneuronal sites, 189
Eye(s)
anatomy, physiology, and
biochemistry, 1773–1778,
1776f
anterior segment, 1774–1777, 1776f
systemic agents affecting, 1792–
1793
anticholinesterase agents and, 246,
250–251
autonomic innervation of, 1773,
1775t, 1776f
in autonomic nervous system, 178t
carbachol and, 224
choline esters and, 223t
eicosanoids and, 950–951
muscarinic antagonists and,
228–229, 233
pilocarpine and, 224
posterior segment, 1774, 1776f,
1777–1778
surface, systemic agents affecting,
1793
systemic agents affecting,
1792–1793
topical application of drugs to, 23
Eyelid(s), 1773
anatomy of, 1774f
systemic agents affecting, 1793
Ezetimibe, 903–904
absorption, 904
adverse effects and side effects of,
904
combination therapy, with statins,
904
contraindications to, 904
drug interactions with, 904
excretion, 904
history of, 903
mechanism of action of, 903–904
pharmacokinetics of, 904, 1840t
surrogate end point experiment
with, 9
therapeutic uses of, 904
F
Facial nerve, 171, 173f, 174
Facilitated diffusion, 19, 94, 94f
Factor VIIa, 851
Factor XII, 929
Factor XIII, 851
Factor Xa inhibitors, oral, 866
FACTREL (gonadorelin hydrochloride),
1119t
False-transmitter concept, 282
Famciclovir, 1596t, 1601
for cutaneous viral infections,
1818
for genital herpes, 1842t
for ophthalmic use, 1782, 1783t
Familial Mediterranean fever,
colchicine for, 996
Familial periodic paralysis,
acetazolamide for, 681
Famotidine, 918
arrhythmias caused by, 832
intravenous doses of, 1313t
pharmacokinetics of, 1816t, 1840t
therapeutic uses of
for gastroesophageal reflux
disease, 1318t
for ulcers, 1319t
FAMVIR (famciclovir), 1596t, 1783t,
1818
FARESTON (toremifene), 1756, 1759
Farnesoid X receptor (FXR), 97, 140t
FAS. See Fetal alcohol syndrome
(FAS)
Fasciculins, 241
Fasciola hepatica, 1449
Fasciolopsis buski, 1449
FASLODEX (fulvestrant), 1756,
1759–1760
Fat, as reservoir, 24
FDA. See Food and Drug
Administration (FDA)
Febrile convulsions, 605
Febuxostat
absorption, 998
adverse effects and side effects of,
998
chemistry, 997
distribution of, 998
drug interactions with, 998
elimination, 998
mechanism of action of, 997–998
pharmacokinetics of, 998
structure of, 997
therapeutic uses of, 998
Fecal excretion, 26
Felbamate, 601–602
FELDENE (piroxicam), 989–990
Felodipine, 761
absorption, fate, and excretion of,
765
as antihypertensive agent, 774t